Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. (ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. Under the terms of the agreement, ADMS shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own.

To receive more information regarding the investigation of Adamas Pharmaceuticals, Inc. please fill out the form below.